Literature DB >> 18318653

Targeted filamentous bacteriophages as therapeutic agents.

Iftach Yacoby1, Itai Benhar.   

Abstract

Bacteriophages (phages) have been used for therapy of bacterial infections, for genetic research, as tools for the discovery of specific target binding proteins and for vaccine development. The aim of this article is to present advances in genetic and chemical engineering of filamentous bacteriophages that facilitated their application for therapeutic purposes. We review studies where phages were applied for in vivo imaging, as gene delivery vehicles and as drug carriers. Target specificity is based on peptides or proteins displayed on the phage coat. The cargo may be a packaged gene incorporated into the phage genome for gene delivery applications, or imaging agents or cytotoxic drugs chemically conjugated at high density onto the phage coat. We believe that the combination of those separately developed methodologies would result in clinical applications of phage-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318653     DOI: 10.1517/17425247.5.3.321

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  8 in total

1.  N-Terminal labeling of filamentous phage to create cancer marker imaging agents.

Authors:  Zachary M Carrico; Michelle E Farkas; Yu Zhou; Sonny C Hsiao; James D Marks; Harshal Chokhawala; Douglas S Clark; Matthew B Francis
Journal:  ACS Nano       Date:  2012-08-06       Impact factor: 15.881

Review 2.  Molecular Sensing with Host Systems for Hyperpolarized 129Xe.

Authors:  Jabadurai Jayapaul; Leif Schröder
Journal:  Molecules       Date:  2020-10-11       Impact factor: 4.411

Review 3.  A century of the phage: past, present and future.

Authors:  George P C Salmond; Peter C Fineran
Journal:  Nat Rev Microbiol       Date:  2015-11-09       Impact factor: 60.633

4.  Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging.

Authors:  Zibo Li; Qiaoling Jin; Chiunwei Huang; Siva Dasa; Liaohai Chen; Li-Peng Yap; Shuanglong Liu; Hancheng Cai; Ryan Park; Peter S Conti
Journal:  Theranostics       Date:  2011-11-18       Impact factor: 11.556

5.  Doxorubicin-conjugated bacteriophages carrying anti-MHC class I chain-related A for targeted cancer therapy in vitro.

Authors:  Achara Phumyen; Siriporn Jantasorn; Amonrat Jumnainsong; Chanvit Leelayuwat
Journal:  Onco Targets Ther       Date:  2014-11-28       Impact factor: 4.147

6.  Bacteriophages engineered to display foreign peptides may become short-circulating phages.

Authors:  Katarzyna Hodyra-Stefaniak; Karolina Lahutta; Joanna Majewska; Zuzanna Kaźmierczak; Dorota Lecion; Marek Harhala; Weronika Kęska; Barbara Owczarek; Ewa Jończyk-Matysiak; Anna Kłopot; Paulina Miernikiewicz; Dominika Kula; Andrzej Górski; Krystyna Dąbrowska
Journal:  Microb Biotechnol       Date:  2019-04-29       Impact factor: 5.813

7.  Modification of a Tumor-Targeting Bacteriophage for Potential Diagnostic Applications.

Authors:  Maya Alexandrovna Dymova; Yaroslav Alexandrovich Utkin; Maria Denisovna Dmitrieva; Elena Vladimirovna Kuligina; Vladimir Alexandrovich Richter
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

8.  Phage display identification of CD100 in human atherosclerotic plaque macrophages and foam cells.

Authors:  Maria Carolina Aquino Luque; Paulo Sampaio Gutierrez; Victor Debbas; Waleska Kerllen Martins; Pedro Puech-Leao; Georgia Porto; Verônica Coelho; Laurence Boumsell; Jorge Kalil; Beatriz Stolf
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.